Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Nguyen Vinh Pham"'
Autor:
András Temesvári, Sigita Aidietienė, Vladimir M. Shipulin, Jae Seung Lee, Pavel Jansa, Nuofu Zhang, Dominik Richard, Nguyen Vinh Pham, Carlos Jerjes Sanchez, Lan Hieu Nguyen, Keertan Dheda, Christian M. Kähler, Olga Barbarash, Piotr Podolec, Tomas Rene Pulido Zamudio, Michael M. Madani, Hyung Kwan Kim, Suree Sompradeekul, Grégoire Prévot, Silvia Ulrich, Luke Howard, Nattapong Jaimchariyatam, Olga Moiseeva, Gulfer Okumus, Zoheir Bshouty, Arintaya Phrommintikul, Friedrich Grimminger, David P. Jenkins, Heinrike Wilkens, Robin Condliffe, Irene Lang, John-David Aubert, Rudolf Speich, Tatiana Mularek-Kubzdela, Nicolas Martin, Hélène Bouvaist, Stephan Rosenkranz, Jun Bean Park, Peter F. Fedullo, Luke S. Howard, Olivier Sanchez, Gérald Simonneau, Ryszard Grzywna, Alexander Chernyavskiy, Zhi-Cheng Jing, Joanna Pepke-Zaba, Anton Vonk Noordegraaf, Andrea Maria D'Armini, Pablo Sepulveda Varela, Gang-Cheng Zhang, Nick H. Kim, Eckhard Mayer, Jerzy Lewczuk, Yuhong Mi, Zeynep Pinar Onen, Ekkehard Grünig, Xian-Yang Zhu, Marion Delcroix, John McConnell, Yuanhua Yang, Jin-Ming Liu, Lyubomyr Solovey, Kelly Papadakis, Xavier Jaïs, Istvan Edes, Tamila Vitalievna Martynyuk, Matthias Held, Kristóf Karlócai, Jarosław Kasprzak, Skaidrius Miliauskas, Hossein Ardeschir Ghofrani, Kim M. Kerr, Volodymyr Gavrysyuk
Publikováno v:
Ghofrani, H A, Simonneau, G, D'Armini, A M, Fedullo, P, Howard, L S, Jaïs, X, Jenkins, D P, Jing, Z C, Madani, M M, Martin, N, Mayer, E, Papadakis, K, Richard, D, Kim, N H, Noordegraaf, A V & MERIT study investigators 2017, ' Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1) : results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study ', The Lancet Respiratory Medicine, vol. 5, no. 10, pp. 785-794 . https://doi.org/10.1016/S2213-2600(17)30305-3
The Lancet Respiratory Medicine, 5(10), 785-794. Elsevier Limited
The Lancet Respiratory Medicine, 5(10), 785-794. Elsevier Limited
Summary Background Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar. Methods The phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36794781d5eccbc59c72cb8cc5a212e5
https://research.vumc.nl/en/publications/4d05f687-13a9-445c-ba49-7129684838f4
https://research.vumc.nl/en/publications/4d05f687-13a9-445c-ba49-7129684838f4
Autor:
Cheol Ho Kim, Peera Buranakitjaroen, Lip Ping Low, Chin Hock Lim, Gregorio Rogelio, Rungroj Krittayaphong, Nelson S. Abelardo, Bernard Wong, Nguyen Vinh Pham, Sungha Park
Publikováno v:
Heart Asia. 8(1)
Hypertension is a common disease, and hypertensive patients are at increased risk of cardiovascular events. The prevalence and socioeconomic burden of hypertension in the Asia-Pacific region are predicted to increase in the coming decades. Effective
Publikováno v:
Asian cardiovascularthoracic annals. 12(4)
From 1992 to 2001, 609 patients with rheumatic heart disease underwent aortic valve replacement with either mitral valve repair ( n = 201) or mitral valve replacement ( n = 408). Follow-up extended to 10 years. Thirty-day mortality was 1.4% for mitra
Autor:
Trong Hiep Chu, Huu Trung Dao, Kim Phuong Phan, Huu Dung Le, van Phan Nguyen, Nguyen Vinh Pham, Alain Carpentier, thi Thuy Anh Dang, Huynh Quang Tri Ho
Publikováno v:
Seminars in thoracic and cardiovascular surgery. Pediatric cardiac surgery annual. 2
Controversy remains regarding whether valve repair is preferable to valve replacement in children suffering from rheumatic mitral valve disease. To answer this question, 130 children aged 3 to 15 years (mean age, 11.8 +/- 2.8 years) undergoing surger
Publikováno v:
CVD Prevention and Control. 4:S171-S172
Publikováno v:
CVD Prevention and Control. 4:S171
Autor:
Adamson C; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK., Kondo T; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK.; Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Jhund PS; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK., de Boer RA; Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Cabrera Honorio JW; Clínica Vesalio, San Borja, Peru., Claggett B; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Desai AS; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Alcocer Gamba MA; Centro de Estudios Clínicos de Querétaro (CECLIQ), Querétaro, México., Al Habeeb W; Cardiac Sciences Department, King Saud University, Riyadh, Saudi Arabia., Hernandez AF; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA., Inzucchi SE; Section of Endocrinology, Yale University School of Medicine, New Haven, CT, USA., Kosiborod MN; Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, MO, USA., Lam CSP; Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; National Heart Centre Singapore & Duke-National University of Singapore, Singapore, Singapore., Langkilde AM; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Lindholm D; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Bachus E; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Litwin SE; Division of Cardiology Medical University of South Carolina and Ralph H. Johnson, Veterans Affairs Medical Center, Charleston, SC, USA., Martinez F; Cordoba National University, Cordoba, Argentina., Petersson M; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Shah SJ; Division of Cardiology, Department of Medicine, and Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Vaduganathan M; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Nguyen Vinh P; Cardiovascular Center, Tam Anh hospital, Tan Tao University, Ho Chi Minh City, Vietnam., Wilderäng U; Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Solomon SD; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., McMurray JJV; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK.
Publikováno v:
European heart journal [Eur Heart J] 2022 Nov 01; Vol. 43 (41), pp. 4406-4417.